Hormone therapy for prostate cancer

Freedland, 2005, Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy, JAMA, 294, 433, 10.1001/jama.294.4.433 Stephenson, 2004, Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy, JAMA, 291, 1325, 10.1001/jama.291.11.1325 Eisenberger, 1998, Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, N Engl J Med, 339, 1306, 10.1056/NEJM199810083391504 2000, Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials, Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2 2000, Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials, Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2 Klotz, 1996, Total androgen blockade for metastatic prostate cancer: history and analysis of the PCTCG overview, CanJ Urol, 3, 102 Moule, 2004, Early vs delayed ADT for PSA recurrence post RP: PSA DT predicts for benefit of early therapy, J Urol, 171, 1141 Scher, 1996, Clinical trials in relapsed prostate cancer: defining the target, J Natl Cancer Inst, 88, 1623, 10.1093/jnci/88.22.1623 Small, 1997, Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm, J Clin Oncol, 15, 382, 10.1200/JCO.1997.15.1.382 Scher, 1997, Bicalutamide for advanced prostate cancer: the natural versus treated histoy of disease, J Clin Oncol, 15, 2928, 10.1200/JCO.1997.15.8.2928 Crawford, 1989, A controlled trial of Ieuprolide with and without flutamide in prostatic carcinoma, N Engl J Med, 321, 419, 10.1056/NEJM198908173210702 Agency for Health Care Policy and Research (AHCPR) Klotz, 2001, Combined androgen blockade in prostate cancer: meta- analyses and associated issues, BJU Int, 87, 806, 10.1046/j.1464-410x.2001.02184.x Bennett CI, Tosteson TD, Schmitt B, et al. Maximum androgen blockade with medical or surgical castration in advanced prostate cancer: a metaanalysis of 9 published randomized controlled trials and 4128 patients Debruyne, 1996, Mezimum androgen blockade with nilutamide combined with orchiectomy in advanced prostate cancer: an updated metaanalysis of 7 randomized, placebo-controlled trials (1191 patients), Eur Urol, 30, 264 The Medical Research Council Prostate Cancer Working Party Investigator's Group, 1997, Immediate versus deferred treatment for advanced prostate cancer: initial results of the medical research council, Brit J Urol, 79, 235, 10.1046/j.1464-410X.1997.d01-6840.x Messing, 1999, Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer, N Engl J Med, 341, 1781, 10.1056/NEJM199912093412401 Uundgren, 1995, Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of follow-up, J Urol, 153, 1580, 10.1016/S0022-5347(01)67466-4 Carducci, 2001, The endothelin-A receptor antagonist Atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: a multinational randomized, double-blind, placebo-controlled trial, ASCO, 694 Klotz, 2004, A re-assessment of the role of combined androgen blockade for advanced prostate cancer, BJU Int, 93, 1177, 10.1111/j.1464-410x.2004.04803.x Han, 2003, Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer, J Urol, 169, 517, 10.1016/S0022-5347(05)63946-8 Partin, 1994, Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer, J Urol, 152, 172, 10.1016/S0022-5347(17)32852-5 Kane, 2003, Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy, Urology, 61, 607, 10.1016/S0090-4295(02)02411-1 Cher, 1998, Limited role of radionucleotide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy, J Urol, 160, 1387, 10.1016/S0022-5347(01)62545-X Okotie, 2004, Predictors of metastatic disease in men with biochemical failure following radical prostatectomy, J Urol, 171, 2260, 10.1097/01.ju.0000127734.01845.99